Metabolic syndrome in antipsychotic naïve patients diagnosed with schizophrenia

Early Intervention in Psychiatry

Volumn 6, Issue 3, 2012, Pages 326-331

  Grover, Sandeep ^a   Nebhinani, Naresh ^a   Chakrabarti, Subho ^a   Parakh, Preeti ^a   Ghormode, Deepak ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Drug na ve; Metabolic syndrome; Prevalence; Schizophrenia

Indexed keywords

HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84864321474     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2011.00321.x     Document Type: Article

References (57)

1. lakka HM, Laaksonen De, Lakka TA etal. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-l6.
2. De Hert M, Vancampfort D, Correll C etal. A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia. Br J Psychiatry 2011; 199: 99-105.
3. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 01123-31.
4. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome - a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2005; 23: 469-80.
5. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
6. Heng D, Ma S, Lee JJM etal. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006; 186: 367-73.
7. Saari KM, Lindeman SM, Viilo KM etal. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland l966 Birth Cohort study. J Clin Psychiatry 2005; 66: 559-63.
8. De Hert MA, vanWinkel R, van Eyck D etal. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87-93.
9. Toalson P, Ahmed S, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004; 6: 152-58.
10. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry 2004; 184: S76-9.
11. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 151: 480-91.
12. lamberti JS, Olson D, Crilly JF etal. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; l63: 1273-76.
13. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007; 191: 23-9.
14. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Cur Diab Rep 2010; 10: 209-16.
15. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119: 4-14.
16. Foley DL, Morley Kl. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011; 68: 609-16.
17. De Hert M, Schreurs V, Sweers K etal. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008; 101: 295-03.
18. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005; 66 (Suppl. 6): 11-20.
19. Taylor DM, McAskill R. Atypical antipsychotic agents and weight gain - a systematic review. Acta Psychiatr Scand 2000; l01: 416-32.
20. Marder SR, Essock SM, Miller AL etal. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-49.
21. Correll CU, Frederickson AM, Kane JM etal. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89: 91-100.
22. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six week prospective study in Indian female patients. Schizophr Res 2007; 95: 247.
23. Saddichha S, Ameen S, Akhtar S. Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics. Aust N Z J Psychiatry 2007; 41: 629.
24. Padmavati R, McCreadie RG, Tirupati S. low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res 20l0; 121: 199-202.
25. Patel JK, Buckley PF, Woolson S etal. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111: 9-16.
26. Phutane VH, Tek C, Chwastiak L etal. Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention? Schizophr Res 2011; 127: 257-61.
27. Perez-Iglesias R, Crespo-Facorro B, Antonio Amado J etal. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 2007; 68: 1733-40.
28. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naïve patients with first-episode psychosis. J Clin Psychiatry 2009; 70: 997-1000.
29. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; l60: 284-89.
30. Spelman LM, Walsh PI, Sharifi N, Collins PJ, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007; 24: 481-85.
31. Arranz B, Rosel P, Ramirez N etal. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naïve first-episode schizophrenia patients. J Clin Psychiatry 2004; 65: 1335-42.
32. Tarricone I, Serretti A, Gozzi BF etal. Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: one-month prospective evaluation. Psychiatry Res 2008; 157: 269-71.
33. Sengupta S, Parrilla-Escobar MA, Klink R etal. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res 2008; 102: 329-36.
34. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders - Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO, 1992.
35. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the national cholesterol education program adult treatment panel definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27: 1182-86.
36. Misra A, Wasir JS, Pandey RM. An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians. Diabetes Care 2005; 28: 398-403.
37. McEvoy JP, Mayer JM, Goff DC etal. Prevalence of metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
38. Bobes J, Arango C, Aranda P, Carmena R, Garcia MG, Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the ClAMORS Study. Schizophr Res 2007; 90: l62-73.
39. Suvisaari JM, Saarni SI, Perälä J etal. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007; 68: l045-55.
40. Cañas F, Banegas JR, Bernardo M, Casademont X, Riesgo Y, Varela C, Ricava Study Group. Cardiovascular risk factors in patients with schizophrenia in Spain: RICAVA study. Schizophr Res 2006; 8l (Suppl. l): l77.
41. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67: 575-83.
42. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005; 27: l930-4l.
43. Huang MC, Lu ML, Tsai CJ etal. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009; l20: 274-80.
44. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 2l: 93-8.
45. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004; 49: 753-60.
46. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007; 4l: 606-l0.
47. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007; 7: l4.
48. Grover S, Nebhinani N, Chakrabarti S, Avasthi A, Kulhara P. Prevalence of metabolic syndrome in subjects receiving clozapine: a study from India. Indian J Pharmacol 20ll; 43: 59l-5.
49. Saddichha S, Narayana M, Shahul A, Sayeed A. Metabolic syndrome in first episode schizophrenia: a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008; l0l: 266-72.
50. Ravikiran M, Bhansali A, Ravi Kumar P etal. Prevalence and risk factors of metabolic syndrome among Asian Indians: a community survey. Diabetes Res Clin Pract 2009; 89: l8l-88.
51. Zipursky RB, Gu H, Green AI. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; l87: 537-43.
52. Graham KA, Perkins DO, Edwards LJ. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; l62: ll8-23.
53. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children. Circulation 2003; l07: l448-53.
54. Giannini C, de Giorgis T, Scarinci A etal. Obese related effects of inflammatory markers and insulin resistance on increased carotid intima media thickness in pre-pubertal children. Atherosclerosis 2008; l97: 448-56.
55. Straker D, Correll CU, Kramer-Ginsberg E etal. Cost-effective screening for the metabolic syndrome in patients treated with second generation antipsychotic medications. Am J Psychiatry 2005; l62: l2l7-2l.
56. Kitabayashi Y, Narumoto J, Kitabayashi M, Fukui K. Body mass index among Japanese inpatients with schizophrenia. Int J Psychiatry Med 2006; 36: 93-l02.
57. Vancampfort D, Knapen J, Probst M etal. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res 20l0; l77: 27l-9.